Pemetrexed Disodium Heptahydrate Induces Apoptosis and Cell-cycle Arrest in Non-small-cell Lung Cancer Carrying an EGFR Exon 19 Deletion.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Carcinoma, Non-Small-Cell Lung
/ genetics
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
DNA Damage
ErbB Receptors
/ genetics
Exons
Gene Deletion
Humans
Lung Neoplasms
/ genetics
Pemetrexed
/ pharmacology
Reactive Oxygen Species
/ metabolism
Signal Transduction
PC9 cells
Pemetrexed
apoptosis
caspases
cell-cycle arrest
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
05
04
2021
revised:
27
04
2021
accepted:
06
05
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
Non-small-cell lung cancer (NSCLC) remains a significant cause of death despite the recent introduction of several improved therapeutics. Pemetrexed disodium heptahydrate (pemetrexed) is currently available in combination with a platinum derivative for patients with advanced non-squamous NSCLC for first-line treatment, and as a single agent for second-line treatment. However, the mechanisms underlying its anticancer activities are still not well understood. In this study, we evaluated the growth inhibitory effects of pemetrexed on PC9 (EGFR exon 19 deletion) cells and elucidated the underlying molecular mechanisms. PC9 cells were treated with pemetrexed and then assessed for the cell viability, morphological and nuclear changes, antigenic alterations, SA-β-gal staining, and changes in protein expression. Pemetrexed reduced the cell viability of PC9 cells and initiated cell morphological changes in a concentration-dependent manner. Pemetrexed significantly induced G This study revealed the mechanisms by which pemetrexed works an anticancer drug in the treatment of NSCLC.
Sections du résumé
BACKGROUND/AIM
Non-small-cell lung cancer (NSCLC) remains a significant cause of death despite the recent introduction of several improved therapeutics. Pemetrexed disodium heptahydrate (pemetrexed) is currently available in combination with a platinum derivative for patients with advanced non-squamous NSCLC for first-line treatment, and as a single agent for second-line treatment. However, the mechanisms underlying its anticancer activities are still not well understood. In this study, we evaluated the growth inhibitory effects of pemetrexed on PC9 (EGFR exon 19 deletion) cells and elucidated the underlying molecular mechanisms.
MATERIALS AND METHODS
PC9 cells were treated with pemetrexed and then assessed for the cell viability, morphological and nuclear changes, antigenic alterations, SA-β-gal staining, and changes in protein expression.
RESULTS
Pemetrexed reduced the cell viability of PC9 cells and initiated cell morphological changes in a concentration-dependent manner. Pemetrexed significantly induced G
CONCLUSION
This study revealed the mechanisms by which pemetrexed works an anticancer drug in the treatment of NSCLC.
Identifiants
pubmed: 34083287
pii: 41/6/2963
doi: 10.21873/anticanres.15078
doi:
Substances chimiques
Antineoplastic Agents
0
Reactive Oxygen Species
0
Pemetrexed
04Q9AIZ7NO
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2963-2977Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.